About
One of the key aims of the Centre is to accelerate the development of the next generation of small molecule drugs by enhancing collaborations between methods development chemists and medicinal chemists. Our Medicinal Chemistry grouping has a proven track record of developing lead compounds for the delivery of future drug candidates, and our Synthetic Methods activities have led to the creation of Liverpool ChiroChem, who are global specialists in the production of chiral building blocks for drug design. The Centre also applies its Synthetic Methods expertise to other areas, such as agrochemistry and molecular electronics.
External collaborations include multinational pharmaceutical companies (e.g. AstraZeneca, GlaxoSmithKline, Eisai), agrochemical companies (e.g. Syngenta, Bayer), Liverpool School of Tropical Medicine (LSTM), the TB Alliance and the Medicines for Malaria Venture (MMV). The Centre is a core member of the CheM62 network, which provides a regional forum for academic and industrial synthetic chemists.
Back to: Department of Chemistry